News tagged with tyrosine
Jak of all trades? Not of leukaemia therapy
About one in five or six cases of adult leukaemia in Western populations relates to so-called chronic myeloid leukaemia, or CML. Treatment of CML usually relies on inhibitors of the abnormal protein that causes the condition ...
Jan 30, 2012 |
not rated yet |
0
The link between TB and a gene mutation that causes lung cancer
Tuberculosis (TB) has been suspected to increase a person's risk of lung cancer because the pulmonary inflammation and fibrosis can induce genetic damage. However, direct evidence of specific genetic changes and the disease ...
Jan 18, 2012 |
not rated yet |
0
Sorafenib effective in patients with non-small cell lung cancer, but low survival rates reported
Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory," according to data presented at the AACR-IASLC Joint Conference on Molecular Origins ...
Jan 10, 2012 |
not rated yet |
0
Enzyme that flips switch on cells' sugar cravings could be anti-cancer target
Cancer cells tend to take up more glucose than healthy cells, and researchers are increasingly interested in exploiting this tendency with drugs that target cancer cells' altered metabolism.
Dec 22, 2011 |
not rated yet |
0
|
Novel experimental agent is highly active in CLL patients, interim study shows
An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other ...
Dec 11, 2011 |
not rated yet |
0
Hope for muscle wasting disease
A health supplement used by bodybuilders could be the key to treating a life-threatening muscular dystrophy affecting hundreds of Australian children, new research shows.
Nov 22, 2011 |
3 / 5 (2) |
0
New TB treatment limits infection while reducing drug resistance
It's estimated that nearly one-third of the world's population -- more than two billion people -- are infected with Mycobacterium tuberculosis. According to the World Health Organization, 5 to 10 percent of infected people ...
Nov 16, 2011 |
not rated yet |
0
Combination therapies for drug-resistant cancers
Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts ...
Oct 10, 2011 |
not rated yet |
0
Leukemia drug reverses tamoxifen-resistance in breast cancer cells
Taking a leukemia chemotherapy drug may help breast cancer patients who don't respond to tamoxifen overcome resistance to the widely-used drug, new research from the Kimmel Cancer Center at Jefferson suggests. ...
Aug 01, 2011 |
not rated yet |
0
|
EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to research presented at the ...
Jul 05, 2011 |
not rated yet |
0
PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumors
A non-invasive PET imaging technique may identify lung cancers that respond best to tyrosine kinase inhibitors (TKIs), allowing doctors to better select patients for personalized therapy, according to research presented at ...
Jul 05, 2011 |
not rated yet |
0
Patients treated with sunitinib and sorafenib respond to flu vaccine
Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared, according to a study in Clinical Cancer Research, a journa ...
Jun 28, 2011 |
not rated yet |
0
Toward a more efficient therapy for a specific form of leukemia
Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius ...
Jun 14, 2011 |
5 / 5 (1) |
0
Novel experimental agent is highly active in CLL patients, interim study shows
An interim analysis of a phase II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated both in patients who are undergoing treatment for the first ...
Jun 06, 2011 |
5 / 5 (1) |
0
|
Taking aim at tumors: Novel way of studying cancer may inspire new treatments
Many of the newest weapons in the war on cancer come in the form of personalized therapies that can target specific changes in an individual's tumor. By disrupting molecular processes in tumor cells, these ...
Apr 19, 2011 |
not rated yet |
0
